Optimal management of taxane acute pain syndrome not clear
the ONA take:
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome (TAPS) remains poorly researched with few studies have evaluated its optimal management, according to a systematic review published online ahead of print in the journal Supportive Care in Cancer.
TAPS is characterized by myalgias and arthralgias beginning 1 to 3 days and lasting 5 to 7 days after taxane-based chemotherapy.
Although it is known to negatively impact patients’ quality of life, the optimal management of TAPS is unclear.
Therefore, researchers at The Ottawa Hospital and University of Ottawa in Ontario, Canada, conducted a systematic review of treatment strategies for TAPS across all tumor sites.
Results showed that neither glutathione nor glutamine were superior to placebo for TAPS. Researchers found that amifostine, a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy, reduced pain in 36% of patients, while gabapentin reduced taxane-induced arthralgias and myalgias in 90% of patients.
“If the management of patients is to be improved, more prospective trials are needed,” the authors conclude.
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome remains poorly researched.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|